Real-world check: is eylea safe and effective for premature babies' eyes?
NCT ID NCT05705258
First seen Nov 01, 2025 · Last updated Jun 09, 2026 · Updated 36 times
Summary
This study follows 75 Japanese babies with retinopathy of prematurity (ROP) who are already being treated with Eylea. Researchers will collect data from routine doctor visits over 6 months to see how safe the drug is and whether it stops the abnormal blood vessel growth that can lead to blindness. No extra tests or treatments are given — it is purely an observation of real-world use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RETINOPATHY OF PREMATURITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Many locations
Multiple Locations, Japan
Conditions
Explore the condition pages connected to this study.